{
    "clinical_study": {
        "@rank": "40098", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1: Fusilev - 10 doses", 
                "arm_group_type": "Experimental", 
                "description": "Fusilev: 5 mg/m2 QID, starting on Day 2 (24 \u00b1 3 hours after Folotyn dose) for a total of 10 doses Day 2: 4 doses Day 3: 4 doses Day 4: 2 doses.\nFolotyn: 30 mg/m2 once weekly for 6 weeks"
            }, 
            {
                "arm_group_label": "Cohort 2: Fusilev - 6 doses", 
                "arm_group_type": "Experimental", 
                "description": "Fusilev: 5 mg/m2 BID, on Days 2 (24 \u00b1 3 hours after Folotyn dose), 3, and 4.\nFolotyn: 30 mg/m2 once weekly for 6 weeks"
            }, 
            {
                "arm_group_label": "Cohort 3: Fusilev - 4 doses", 
                "arm_group_type": "Experimental", 
                "description": "5 mg/m2 BID, on Days 2 (24 \u00b1 3 hours after Folotyn dose) and 3.\nFolotyn: 30 mg/m2 once weekly for 6 weeks"
            }, 
            {
                "arm_group_label": "Cohort 4: Fusilev - 2 doses", 
                "arm_group_type": "Experimental", 
                "description": "5 mg/m2 BID, on Day 2 (24 \u00b1 3 hours after Folotyn dose.\nFolotyn: 30 mg/m2 once weekly for 6 weeks"
            }, 
            {
                "arm_group_label": "Cohort 5: Fusilev - 1 dose", 
                "arm_group_type": "Experimental", 
                "description": "Fusilev: 5 mg/m2 once on Day 2.\nFolotyn: 30 mg/m2 once weekly for 6 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is determine the optimal dose and schedule of Fusilev to prevent\n      or reduce Mucositis in patients with Non-Hodgkin's Lymphoma receiving Folotyn treatment."
        }, 
        "brief_title": "Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Mucositis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open label, uncontrolled, nonrandomized, multicenter, dose finding, Phase 1 study\n      primarily to determine the optimal dose and schedule of Fusilev to prevent or reduce\n      Folotyn-related Grade 3 or higher oral Mucositis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years of age\n\n          -  Patients with relapsed or refractory NHL who are eligible for Folotyn     treatment.\n             Patient has histologically/cytologically confirmed, measurable (lesion or node \u2265 2 cm\n             by computed tomography [CT]\n\n          -  Progressive disease or persistent disease after at least 1 prior treatment\n\n          -  ECOG performance status \u2264 2\n\n          -  Adequate hematological, hepatic, and renal function\n\n        Exclusion Criteria:\n\n          -  Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of\n             the cervix)\n\n          -  Congestive heart failure\n\n          -  Uncontrolled hypertension\n\n          -  Known human immunodeficiency virus (HIV)-positive diagnosis\n\n          -  Active uncontrolled infection, underlying medical condition, or other serious illness\n             that would impair the ability of the patient to receive protocol treatment\n\n          -  Major surgery within 14 days of enrollment\n\n          -  Pregnant or breast-feeding women\n\n          -  Symptomatic central nervous system (CNS) metastases or lesions for which treatment is\n             required. Patients who received prophylactic CNS treatment are eligible\n\n          -  Previous exposure to pralatrexate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789723", 
            "org_study_id": "SPI-FUS-12-102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1: Fusilev - 10 doses", 
                    "Cohort 2: Fusilev - 6 doses", 
                    "Cohort 3: Fusilev - 4 doses", 
                    "Cohort 4: Fusilev - 2 doses", 
                    "Cohort 5: Fusilev - 1 dose"
                ], 
                "description": "Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 \u00b1 3 hours after Folotyn administration depending on the dose cohort.", 
                "intervention_name": "Fusilev", 
                "intervention_type": "Drug", 
                "other_name": "Fusilev - (Levoleucovorin)"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1: Fusilev - 10 doses", 
                    "Cohort 2: Fusilev - 6 doses", 
                    "Cohort 3: Fusilev - 4 doses", 
                    "Cohort 4: Fusilev - 2 doses", 
                    "Cohort 5: Fusilev - 1 dose"
                ], 
                "description": "A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.", 
                "intervention_name": "Folotyn", 
                "intervention_type": "Drug", 
                "other_name": "Folotyn - (Pralatrexate)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 23, 2013", 
        "number_of_arms": "5", 
        "official_title": "An Open Label, Multicenter, Dose Finding, Phase 1 Study of Fusilev\u00ae (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Receiving Folotyn\u00ae (Pralatrexate)", 
        "other_outcome": {
            "description": "To determine overall response rate (ORR) of Folotyn in relapsed or refractory Non-Hodgkin's lymphoma other than PTCL", 
            "measure": "Overall Response Rate (ORR)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 24 months"
        }, 
        "overall_official": {
            "affiliation": "Columbia University", 
            "last_name": "Ahmed Sawas, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The patient will be seen in the clinic for an oral mucositis assessment at baseline. During the 6 weeks of Folotyn treatment, oral mucositis assessment will be performed weekly prior to each Folotyn dose and again on Day 4 (prior to the Fusilev dose when applicable) by a qualified health care professional. Patients will complete an Oral Mucositis Daily Questionnaire (OMQD) starting at Day 1 of Week 1 and ending at the End of Treatment Visit.", 
            "measure": "Optimal dose and schedule of Fusilev to prevent or reduce mucositis", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789723"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the impact of Fusilev on the number of Folotyn-related dose modifications secondary to oral mucositis To determine the impact of Fusilev on the frequency of Folotyn-related oral mucositis To determine the impact of Fusilev on the number of Folotyn doses delivered", 
                "measure": "Impact of Fusilev on Folotyn related Oral Mucositis", 
                "safety_issue": "Yes", 
                "time_frame": "7 weeks"
            }, 
            {
                "description": "To determine the relationship between Fusilev use and oral mucositis as a function of the pretreatment homocysteine (HCY) and methylmalonic acid (MMA) levels", 
                "measure": "Relationship between Fusilev use and oral mucositis", 
                "safety_issue": "Yes", 
                "time_frame": "7 weeks"
            }
        ], 
        "source": "Spectrum Pharmaceuticals, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spectrum Pharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}